Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Arief Lalmohamed"'
Autor:
John Haanen, Arief Lalmohamed, Jos Beijnen, Marjolein Metselaar-Albers, Irma Meijerman, Ferdi Engels
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background The role of antibiotics in malignancies treated with immune checkpoint inhibitors (ICI) remains unclear. Several studies suggested a detrimental impact of antibiotic use on the response to ICI, but were susceptible to confounding by indica
Externí odkaz:
https://doaj.org/article/fe1cb478e39442389d268f3b42a38ee0
Autor:
Thijs ten Doesschate, Simone J. C. F. M. Moorlag, Thomas W. van der Vaart, Esther Taks, Priya Debisarun, Jaap ten Oever, Chantal P. Bleeker-Rovers, Patricia Bruijning Verhagen, Arief Lalmohamed, Rob ter Heine, Reinout van Crevel, Janneke van de Wijgert, Axel B. Janssen, Marc J. Bonten, Cornelis H. van Werkhoven, Mihai G. Netea, on behalf of the BCG-CORONA study team#
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-2 (2020)
Abstract Objectives The objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination. Trial design Two s
Externí odkaz:
https://doaj.org/article/cdc83b13bfe146958bfc1645d0fbaaef
Autor:
Thijs ten Doesschate, Simone J. C. F. M. Moorlag, Thomas W. van der Vaart, Esther Taks, Priya Debisarun, Jaap ten Oever, Chantal P. Bleeker-Rovers, Patricia Bruijning Verhagen, Arief Lalmohamed, Rob ter Heine, Reinout van Crevel, Janneke van de Wijgert, Axel B. Janssen, Marc J. Bonten, Cornelis H. van Werkhoven, Mihai G. Netea, on behalf of the BCG-CORONA study team#
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/7319183289f043b2b688733f5bea7404
Autor:
Hilda J I de Jong, Jan Willem Cohen Tervaert, Arief Lalmohamed, Frank de Vries, Rob J Vandebriel, Henk van Loveren, Olaf H Klungel, Tjeerd P van Staa
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0193297 (2018)
We examined the association between statin use and the risk of rheumatoid arthritis (RA), with special focus on describing the patterns of risks of RA during statin exposure in a large population-based cohort in the United Kingdom. In the Clinical Pr
Externí odkaz:
https://doaj.org/article/46b6bf0956e64b249549f86619e413d5
Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
Autor:
Rogier Wvan der Zanden, Frank de Vries, Arief Lalmohamed, Johanna H M Driessen, Anthonius de Boer, Gernot Rohde, Cees Neef, Casper den Heijer
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139367 (2015)
Dipeptidyl-peptidase-4 inhibitors (DPP4Is) are drugs for the treatment of type 2 diabetes mellitus (T2DM). There is increasing evidence that DPP4Is may result in suppression of the immune system and may increase the risk of infections such as pneumon
Externí odkaz:
https://doaj.org/article/f08d04bd3d74430f934fada499d78877
Autor:
Arief Lalmohamed, Alexander J MacGregor, Frank de Vries, Hubertus G M Leufkens, Tjeerd P van Staa
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e65891 (2013)
BackgroundThere are concerns that metal-on-metal hip implants may cause cancer. The objective of this study was to evaluate patterns and timing of risk of cancer in patients with metal-on-metal total hip replacements (THR).MethodsIn a linkage study b
Externí odkaz:
https://doaj.org/article/23737848b9e547e8b06bbc3cb86185d0
Autor:
Thijs ten Doesschate, Thomas W. van der Vaart, Priya A. Debisarun, Esther Taks, Simone J.C.F.M. Moorlag, Nienke Paternotte, Wim G. Boersma, Vincent P. Kuiper, Anna H.E. Roukens, Bart J.A. Rijnders, Andreas Voss, Karin M. Veerman, Angele P.M. Kerckhoffs, Jaap ten Oever, Reinout van Crevel, Cees van Nieuwkoop, Arief Lalmohamed, Janneke H.H.M. van de Wijgert, Mihai G. Netea, Marc J.M. Bonten, Cornelis H. van Werkhoven
Publikováno v:
Clinical Microbiology and Infection, 28, 9, pp. 1278-1285
Clinical Microbiology and Infection, 28(9), 1278-1285. ELSEVIER SCI LTD
Clinical Microbiology and Infection, 28(9), 1278-1285. Elsevier Ltd.
Clinical Microbiology and Infection, 28(9), 1278-1285
ten Doesschate, T, van der Vaart, T W, Debisarun, P A, Taks, E, Moorlag, S J C F M, Paternotte, N, Boersma, W G, Kuiper, V P, Roukens, A H E, Rijnders, B J A, Voss, A, Veerman, K M, Kerckhoffs, A P M, Oever, J T, van Crevel, R, van Nieuwkoop, C, Lalmohamed, A, van de Wijgert, J H H M, Netea, M G, Bonten, M J M & van Werkhoven, C H 2022, ' Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial ', Clinical Microbiology and Infection, vol. 28, no. 9, pp. 1278-1285 . https://doi.org/10.1016/j.cmi.2022.04.009
Clinical Microbiology and Infection, 28, 1278-1285
Clinical Microbiology and Infection, 28(9), 1278-1285. ELSEVIER SCI LTD
Clinical Microbiology and Infection, 28(9), 1278-1285. Elsevier Ltd.
Clinical Microbiology and Infection, 28(9), 1278-1285
ten Doesschate, T, van der Vaart, T W, Debisarun, P A, Taks, E, Moorlag, S J C F M, Paternotte, N, Boersma, W G, Kuiper, V P, Roukens, A H E, Rijnders, B J A, Voss, A, Veerman, K M, Kerckhoffs, A P M, Oever, J T, van Crevel, R, van Nieuwkoop, C, Lalmohamed, A, van de Wijgert, J H H M, Netea, M G, Bonten, M J M & van Werkhoven, C H 2022, ' Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial ', Clinical Microbiology and Infection, vol. 28, no. 9, pp. 1278-1285 . https://doi.org/10.1016/j.cmi.2022.04.009
Clinical Microbiology and Infection, 28, 1278-1285
Objectives: The COVID-19 pandemic increases healthcare worker (HCW) absenteeism. The bacillus Calmette-Gue?rin (BCG) vaccine may provide non-specific protection against respiratory infections through enhancement of trained immunity. We investigated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0978cbd17d01bbafaf6d1b9840fdcdf1
http://www.scopus.com/inward/record.url?scp=85130805747&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85130805747&partnerID=8YFLogxK
Autor:
A. Laura Nijstad, Wan-Yu Chu, Evelien de Vos-Kerkhof, Catherine F. Enters-Weijnen, Mirjam E. van de Velde, Gertjan J. L. Kaspers, Shelby Barnett, Gareth J. Veal, Arief Lalmohamed, C. Michel Zwaan, Alwin D. R. Huitema
Publikováno v:
Pharmaceutical Research, 39(10), 2487-2495. Springer New York
Nijstad, A L, Chu, W-Y, de Vos-Kerkhof, E, Enters-Weijnen, C F, van de Velde, M E, Kaspers, G J L, Barnett, S, Veal, G J, Lalmohamed, A, Zwaan, C M & Huitema, A D R 2022, ' A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children ', Pharmaceutical Research, vol. 39, no. 10, pp. 2487-2495 . https://doi.org/10.1007/s11095-022-03364-1
Nijstad, A L, Chu, W-Y, de Vos-Kerkhof, E, Enters-Weijnen, C F, van de Velde, M E, Kaspers, G J L, Barnett, S, Veal, G J, Lalmohamed, A, Zwaan, C M & Huitema, A D R 2022, ' A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children ', Pharmaceutical Research, vol. 39, no. 10, pp. 2487-2495 . https://doi.org/10.1007/s11095-022-03364-1
Background Vincristine, a chemotherapeutic agent that extensively binds to β-tubulin, is commonly dosed at 1.4–2.0 mg/m2 capped at 2 mg. For infants, doses vary from 0.025–0.05 mg/kg or 50–80% of the mg/m2 dose. However, evidence for lower dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3252a80dc4a529e37c63fb381515ea87
https://doi.org/10.1007/s11095-022-03364-1
https://doi.org/10.1007/s11095-022-03364-1
Autor:
A. Laura Nijstad, Shelby Barnett, Arief Lalmohamed, Inez M. Bérénos, Elizabeth Parke, Vickyanne Carruthers, Deborah A. Tweddle, Jordon Kong, C. Michel Zwaan, Alwin D.R. Huitema, Gareth J. Veal
Publikováno v:
European Journal of Cancer. 164:137-154
Cancer in neonates and infants is a rare but challenging entity. Treatment is complicated by marked physiological changes during the first year of life, excess rates of toxicity, mortality, and late effects. Dose optimisation of chemotherapeutics may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::646db6b116d79c082194144be1414d81
https://doi.org/10.1016/j.ejca.2021.11.001
https://doi.org/10.1016/j.ejca.2021.11.001
Autor:
Eva L. Koekenbier, Konstantin Fohse, Josephine S. van de Maat, Jan Jelrik Oosterheert, Cees van Nieuwkoop, Jacobien J. Hoogerwerf, Martin P. Grobusch, Maurice A.A.J. van den Bosch, Janneke H.H. van de Wijgert, Mihai G. Netea, Frits R. Rosendaal, Marc J.M. Bonten, C.H. (Henri) van Werkhoven, Astrid Aardenburg-van Huisstede, Heidi S.M. Ammerlaan, Willem G. Boersma, Kees Brinkman, Patricia C.J. Bruijning-Verhagen, Reinout van Crevel, Corine Delsing, Thijs ten Doesschaten, Anton S.M. Dofferhoff, Ruud Duijkers, Rolf H.H. Groenwold, Corine de Haas, Robert-Jan Hassing, Marieke L.A. de Hoog, Susanne M. Huijts, Astrid van Hylckama-Vlieg, Eefje Jong, Hanna K. de Jong, Martijn Knap, Michael Koenders, Ilse J.E. Kouijzer, Henk Kramer, Roel van de Laar, Arief Lalmohamed, Karel-Jan D.F. Lensen, Willem M. Lijfering, Fabienne Magdelijns, Bob Meek, Rutger A. Middelburg, Hazra S. Moeniralam, Simon P. Mooijaart, Barbara C. van Munster, Jaap ten Oever, Marc Padros Goossens, Vincent Peters, Douwe F. Postma, Niels Pouw, Herre J. Reesink, Marieke J.A. de Regt, Anneli C.J. van der Reijden, R. Schaakxs, Kitty Slieker, Robbert J. Slingerland, Nicolette L.J. van Sluis, Coen D.A. Stehouwer, Frank van de Veerdonk, Annelies Verbon
Publikováno v:
Clinical Microbiology and Infection, 29, 6, pp. 781-788
Clinical Microbiology and Infection. ELSEVIER SCI LTD
Clinical microbiology and infection. Elsevier Limited
Clinical Microbiology and Infection, 29, 781-788
Clinical Microbiology and Infection. ELSEVIER SCI LTD
Clinical microbiology and infection. Elsevier Limited
Clinical Microbiology and Infection, 29, 781-788
Contains fulltext : 293489.pdf (Publisher’s version ) (Open Access) OBJECTIVES: To test whether Bacillus Calmette-Guérin (BCG) vaccination would reduce the incidence of COVID-19 and other respiratory tract infections (RTIs) in older adults with on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8c3a684309d13bffc06a6419df8592
https://doi.org/10.1016/j.cmi.2023.01.019
https://doi.org/10.1016/j.cmi.2023.01.019